Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edap Tms S.A. (EDAP)
NASDAQ:EDAP
Holding EDAP?
Track your performance easily
EDAP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.71 - $8.50
Previous Close$3.08
Volume42.40K
Average Volume (3M)55.43K
Market Cap
$114.28M
Enterprise Value$75.49M
Total Cash (Recent Filing)€43.47M
Total Debt (Recent Filing)€8.48M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 13, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding37,103,779
10 Day Avg. Volume31,565
30 Day Avg. Volume55,434
Standard Deviation0.16
R-Squared0.02
Alpha0.00886
Financial Highlights & Ratios
Price to Book (P/B)1.99
Price to Sales (P/S)5.24
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.67Price Target Upside315.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EDAP TMS News
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsData from a single-arm Phase 2 Study published in June indicated that 89.8% (n=54) and 81.6% (n=49) of patients reported reduction of acute pelvic pain at three and six months, respectively, following HIFU treatment.
Procedure VolumeProcedure volume continues to grow, indicating continued adoption of HIFU among urologists.
Reimbursement ApprovalRecent approval of reimbursement in Switzerland strengthened company’s European and Middle Eastern commercial presence through the appointment of two new managers in Europe.
Bears Say
Clinical TrialsThe study failed to meet the primary endpoint of reduced acute pelvic pain in the HIFU-treated arm compared to the Sham-treated arm at three months post-procedure.
Study PerformanceThe 60-patient study failed to meet the primary endpoint of reduced acute pelvic pain in the HIFU-treated arm compared to the Sham-treated arm.
Study ResultsInterim results reported demonstrated that the study failed to meet the primary endpoint of reduced acute pelvic pain in the HIFU-treated arm compared to the Sham-treated arm.
---
Ownership Overview
0.00%
Insiders
4.18% Mutual Funds
30.65% Other Institutional Investors
65.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EDAP FAQ
What was Edap Tms S.A.’s price range in the past 12 months?
Edap Tms S.A. lowest stock price was $2.71 and its highest was $8.50 in the past 12 months.
What is Edap Tms S.A.’s market cap?
Currently, no data Available
When is Edap Tms S.A.’s upcoming earnings report date?
Edap Tms S.A.’s upcoming earnings report date is Nov 13, 2024 which is in 54 days.
How were Edap Tms S.A.’s earnings last quarter?
Edap Tms S.A. released its earnings results on Aug 28, 2024. The company reported -$0.177 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.035.
Is Edap Tms S.A. overvalued?
According to Wall Street analysts Edap Tms S.A.’s price is currently Undervalued.
Does Edap Tms S.A. pay dividends?
Edap Tms S.A. does not currently pay dividends.
What is Edap Tms S.A.’s EPS estimate?
Edap Tms S.A.’s EPS estimate is -$0.16.
How many shares outstanding does Edap Tms S.A. have?
Edap Tms S.A. has 37,103,780 shares outstanding.
What happened to Edap Tms S.A.’s price movement after its last earnings report?
Edap Tms S.A. reported an EPS of -$0.177 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went up 4.181%.
Which hedge fund is a major shareholder of Edap Tms S.A.?
Among the largest hedge funds holding Edap Tms S.A.’s share is Bruce & Co., Inc.. It holds Edap Tms S.A.’s shares valued at 3M.
---
EDAP TMS Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (315.41% Upside)
$12.67 (315.41% Upside)
Blogger Sentiment
Bullish
EDAP Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.16%
12-Months-Change
Fundamentals
Return on Equity
-35.41%
Trailing 12-Months
Asset Growth
-15.33%
Trailing 12-Months
Company Description
Edap Tms S.A.
EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.
---
EDAP Earnings Call
Q2 2024
0:00 / 0:00
---
EDAP Stock 12 Month Forecast
Average Price Target
$12.67
▲(315.41% Upside)
Technical Analysis
Best Analysts Covering EDAP
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-17.51%
reiterated a buy rating 22 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -17.51% per trade.
---